Phase III clinical trial - VADS

SANTAL ( GORTEC 2016-02)
VADS
Ouvert depuis le: 03.21.2019
Site: Paris
Public cible
Adulte
A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors
Description de l'essai

A phase III, multicenter, randomized, open-label, french study comparing:;-Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction);-Arm B: Radiotherapy (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction) + concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 cycles)